IRTUM – Institutional Repository of the Technical University of Moldova

The Prevalence of Allele Frequencies of CYP2C19 Polymorphisms of Clinically Important Drug-Metabolizing Enzymes CYP2C19 in Moldova Healthy Population

Show simple item record

dc.contributor.author DOGOT, Marta
dc.contributor.author GALEA-ABDUSA, Daniela
dc.contributor.author BUZA, Anastasia
dc.contributor.author CUROCICHIN, Ghenadie
dc.contributor.author CAPROS, Natalia
dc.date.accessioned 2023-11-16T07:16:21Z
dc.date.available 2023-11-16T07:16:21Z
dc.date.issued 2023
dc.identifier.citation DOGOT, Marta, GALEA-ABDUSA, Daniela, BUZA, Anastasia et al. The Prevalence of Allele Frequencies of CYP2C19 Polymorphisms of Clinically Important Drug-Metabolizing Enzymes CYP2C19 in Moldova Healthy Population. In: 6th International Conference on Nanotechnologies and Biomedical Engineering: proc. of ICNBME-2023, 20–23, 2023, Chisinau, vol. 2: Biomedical Engineering and New Technologies for Diagnosis, Treatment, and Rehabilitation, 2023, p. 392-401. ISBN 978-3-031-42781-7. e-ISBN 978-3-031-42782-4. en_US
dc.identifier.isbn 978-3-031-42781-7
dc.identifier.isbn 978-3-031-42782-4
dc.identifier.uri https://doi.org/10.1007/978-3-031-42782-4_42
dc.identifier.uri http://repository.utm.md/handle/5014/24850
dc.description Acces full text - https://doi.org/10.1007/978-3-031-42782-4_42 en_US
dc.description.abstract Genetic polymorphisms of drug-metabolizing enzymes, such as cytochrome P450 oxidases, can alter the pharmacokinetic properties of administered drugs, leading to variability in drug responses. Prior knowledge of allele frequencies of cytochrome P450 polymorphisms in a population is crucial. In the current study, the frequency of the CYP2C19*2, CYP2C19*3, CYP2C19*17 alleles, genotypes and phenotype in healthy population of Republic of Moldova was examined. Tests for polymorphisms of CYP2C19 was performed using method TaqMan® SNP Genotyping Assays in 430 healthy subjects, assessing the phenotypes, which included normal metabolizer (NM), intermediate metabolizer (IM), poor metabolizer (PM), rapid metabolizers (RM) and ultrarapid metabolizer (UM). 112 individuals (26.2%) were CYP2C19*1/*2 heterozygotes, 7 (1.6%) were CYP2C19*2/*2 homozygotes, 119 subjects (28.4%) were CYP2C19*1/*17 heterozygotes and 31 subjects (7.4%) were CYP2C19*17/*17 homozygotes, while 1 individual (0.2%) was a CYP2C19*1/*3 compound heterozygote. Therefore, 7 individuals CYP2C19*2/*2 homozygotes (1.6%) are predicted to be CYP2C19 PM. The allele frequencies for CYP2C19*2, *3 and *17 was 14.7%, 0.1% and 21.6%, respectively. The results of this study provide important information about the distribution of CYP2C19 genetic variants in the healthy population of the Republic of Moldova. These findings may have implications for understanding population differences in drug responses, and they support the potential application of genetic testing in medical practice to guide personalized treatment approaches. en_US
dc.language.iso en en_US
dc.publisher Springer Nature Switzerland en_US
dc.rights Attribution-NonCommercial-NoDerivs 3.0 United States *
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/3.0/us/ *
dc.subject polymorphisms en_US
dc.subject genotyping en_US
dc.subject Moldova population en_US
dc.subject drug-metabolizing enzymes en_US
dc.title The Prevalence of Allele Frequencies of CYP2C19 Polymorphisms of Clinically Important Drug-Metabolizing Enzymes CYP2C19 in Moldova Healthy Population en_US
dc.type Article en_US


Files in this item

The following license files are associated with this item:

This item appears in the following Collection(s)

  • 2023
    6th International Conference on Nanotechnologies and Biomedical Engineering, September 20–23, 2023, Chisinau, Moldova

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States

Search DSpace


Browse

My Account